Point72 Asset Management
XENE icon

Point72 Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Point72 Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$541K Hold
9,300
– – ﹤0.01% 3083
2025
Q4 		$417K Buy
+9,300
New +$391K ﹤0.01% 3326

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asset Management's XENE Position: Q2 2025 in Review

Point72 Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 209,759 shares — an estimated $7.04M sold.

Point72 Asset Management first reported a position in XENE in Q1 2015 and held it in 40 quarters. The position peaked at $93.5M in Q4 2021. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Point72 Asset Management reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 209,759 Xenon Pharmaceuticals shares in Q2 2025, an estimated $7.04M.
  • Point72 Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 40 quarters.
  • Point72 Asset Management's Xenon Pharmaceuticals position peaked at $93.5M in Q4 2021.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.